Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription

The nuclear isoform of the LIM domain protein Trip6 integrates activating and repressing signals at the promoter-bound glucocorticoid receptor

Trip6 belongs to a family of cytosolic LIM domain proteins involved in cell adhesion and migration. Recent findings show that these proteins also regulate transcription. We have previously reported that nTrip6, a nuclear isoform of Trip6, acts as a co-activator for AP-1 and NF-kappaB transcription factors. Here we report that nTrip6 is an essential regulator of glucocorticoid receptor (GR) transcriptional activity. nTrip6 is recruited to GR-bound promoters through an interaction with GR, and increases GR-mediated transcription. nTrip6 is also essential for the transrepression of GR by NF-kappaB and AP-1. The interaction of nTrip6 with NF-kappaB and AP-1 at a GR-bound promoter is required for the repression. Thus, nTrip6 serves as the molecular mediator of the crosstalk between nuclear receptors and other transcription factors in that it assembles these factors at promoters. Our results reveal an essential role for LIM domain proteins in the integration of positive and negative signals at target promoters.

Effects of cholinergic lesions produced by infusions of 192 IgG-saporin on glucocorticoid receptor mRNA expression in hippocampus and medial prefrontal cortex of the rat

Principal neurons in the hippocampus and prefrontal cortex of the rat have been identified as targets for glucocorticoids involved in the hypothalamic-pituitary-adrenocortical stress response. Alterations in mRNA expression for glucocorticoid receptors in each of these regions have been shown to affect the negative feedback response to corticosterone following an acute stressor. Both decreases in forebrain glucocorticoid receptors and in the efficiency of adrenocortical feedback have been observed in normal aging, and have been selectively induced with experimental lesions or manipulations in neurotransmitter systems. The current study investigated the possibility that a loss of cholinergic support from cells in the basal forebrain, a hallmark of aging, contributes to the selective age-related loss of glucocorticoid receptor mRNA expression at cholinoceptive target sites that include the hippocampus and medial prefrontal cortex. Lesions of the basal forebrain cholinergic system in young adult rats were made by microinjections of the immunotoxin 192 IgG-saporin into the medial septum/vertical limb of the diagonal band and substantia innominata/nucleus basalis. Basal levels of circulating glucocorticoids were unaffected by the lesions. Analysis of both mineralocorticoid and glucocorticoid receptor mRNA expression revealed a significant decrease in glucocorticoid receptor mRNA in the hippocampus and medial prefrontal cortex, with spared expression at subcortical sites and no detectable change in mineralocorticoid receptor mRNA in any of the examined regions. Thus, rats with lesions of the basal forebrain cholinergic system recapitulate some of the detrimental effects of aging associated with glucocorticoid-mediated stress pathways in the brain.

Antagonism of glucocorticoid receptor transactivity and cell growth inhibition by transforming growth factor-beta through AP-1-mediated transcriptional repression

We have examined the interaction of the glucocorticoid receptor (GR) and transforming growth factor-beta (TGF-beta) signal pathways because of their mutual involvement in the regulation of cell growth, development and differentiation. Most studies of this cross-talk event have focused on the effects of glucocorticoids (GCs) on TGF-beta responses. In this work, we show that TGF-beta can antagonize dexamethasone (Dex)-mediated growth suppression in mouse fibrosarcoma L929 cells. TGF-beta also repressed GR-mediated reporter (pMMTV-CAT) gene expression in a concentration-dependent manner, with an IC(50) of 5 ng/ml of TGF-beta. Maximal inhibition (76%) was observed at 10 ng/ml of TGF-beta. Conversely, Dex inhibited TGF-beta-mediated promoter (p3TP-Lux) activity in these same cells. As TGF-beta inhibition of GR-mediated gene expression occurred after Dex-mediated nuclear translocation of GR, we conclude that TGF-beta inhibition of GR signaling occurs at the level of GR-mediated transcription activity. However, TGF-beta did not repress GR-mediated gene expression using the pGRE(2)E1B-CAT minimal promoter construct, suggesting that TGF-beta did not inhibit intrinsic GR activity but, rather, required DNA-binding factor(s) distinct from GR. As the MMTV promoter contains several putative AP-1 binding sites, we hypothesized that AP-1, a transcription factor composed of c-jun and c-fos proteins, might be involved in the TGF-beta inhibition of GR functions. Curcumin, a potent inhibitor of AP-1 expression, completely abolished the inhibitory effect of TGF-beta on GR-mediated gene expression without affecting GR activity in the absence of TGF-beta, and this drug blocked TGF-beta-induced binding of AP-1 to a response element derived from the MMTV sequence. Furthermore, curcumin abolished TGF-beta inhibition of Dex-induced growth suppression. Taken as a whole, our data suggest that TGF-beta can antagonize the growth inhibitory properties of GR by blocking GR transactivity at complex promoters through a mechanism involving transcriptional repression by DNA-bound AP-1.

Suppression of granulocyte-macrophage colony-stimulating factor expression by glucocorticoids involves inhibition of enhancer function by the glucocorticoid receptor binding to composite NF-AT/activator protein-1 elements

Increased expression of a number of cytokines including GM-CSF is associated with chronic inflammatory conditions such as bronchial asthma. Glucocorticoid therapy results in suppression of cytokine levels by a mechanism(s) not yet fully understood. We have examined regulation of GM-CSF expression by the synthetic glucocorticoid dexamethasone in human T cells. Transient transfection assays with reporter constructs revealed that dexamethasone inhibited the function of the GM-CSF enhancer, but had no effect on regulation of GM-CSF expression occurring through the proximal promoter. Activation of the GM-CSF enhancer involves cooperative interaction between the transcription factors NF-AT and AP-1. We demonstrate here that glucocorticoid-mediated inhibition of enhancer function involves glucocorticoid receptor (GR) binding to the NF-AT/AP-1 sites. These elements, which do not constitute recognizable glucocorticoid response elements, support binding of the GR, primarily as a dimer. This binding correlates with the ability of dexamethasone to inhibit enhancer activity of the NF-AT/AP-1 elements, suggesting a competition between NF-AT/AP-1 proteins and GR.

The delayed induction of c-jun in apoptotic human leukemic lymphoblasts is primarily transcriptional

Because of their ability to induce lymphoid cell apoptosis, glucocorticoids have been used for decades to treat certain human leukemias and lymphomas. Studies presented in this paper complement our previous work demonstrating that sustained induction of the proto-oncogene c-jun plays a crucial role in the glucocorticoid-induced apoptotic pathway in CEM cells, human leukemic lymphoblasts. Results from measurements of c-jun mRNA half-life with RNase protection assays and of transcription by nuclear run-on assays indicate that, in the dexamethasone-sensitive cloned CEM-C7 cells, c-jun is induced at the transcriptional level. Consideration of time-course, however, suggested that this might be a secondary or possibly a delayed primary response. Use of cycloheximide to block protein synthesis strongly induced c-jun mRNA, suggesting that there had been relief from a labile protein repressor of transcription. Comparing the level of induction by cycloheximide with that of dexamethasone indicated that the two did not induce by an identical mechanism. The high induction by cycloheximide obscured simple interpretation of elevated c-jun mRNA levels after concomitant administration of cycloheximide and dexamethasone. This was resolved by nuclear run-on experiments, which showed that the dexamethasone induction of c-jun mRNA in this system does require protein synthesis.

Transcription control and neuronal differentiation by agents that activate the LXR nuclear receptor family

LXR and PPAR receptors belong to the nuclear receptor superfamily of transcriptional activating factors. Using ligand-dependent transcription assays, we found that 5-tetradecyloxy-2-furancarboxylic acid (TOFA) transactivates chimeric receptors composed of the glucocorticoid receptor DNA binding domain and the ligand binding regions of PPARalpha, PPARbeta (NUC-1) and LXRbeta (NER) receptors. In the same assays, ligands for PPARs (oleic acid, WY-14643 and L-631,033) and LXRs (hydroxycholesterols) maintain their respective receptor selectivity. TOFA and hydroxycholesterols also stimulate transcription from a minimal fibrinogen promoter that is under the control of AP-1 or NF-kappaB transcription factor binding sites. In addition to their effects on transcription, these LXRbeta activators induce neuronal differentiation in rat pheochromocytoma cells. TOFA and the natural LXR agonist, 22 (R)-hydroxycholesterol, stimulate neurite outgrowth in 55 and 28% of cells, respectively. No neurite outgrowth was induced by the related 22(S)-hydroxycholesterol, which does not activate the LXR family. These results suggest that the hydroxycholesterol signaling pathway has a complex effect on transcription that mediates the activity of TOFA and hydroxycholesterol on neuronal differentiation in pheochromocytoma cells.

Neurotransmitters activate the human estrogen receptor in a neuroblastoma cell line

The human neuroblastoma cell line SK-N-SH has been used as a model system to study the interactions of the human estrogen receptor (hER) with neurotransmitters. We have successfully transfected these cells using an adenoviral delivery system and have reconstituted ligand-dependent responses to estradiol and ligand-independent responses to a series of dopamine D1 receptor agonists. The full agonist for the D1 receptor, SKF 82958, shows a robust activation of hER, comparable to that induced by estradiol. This activation is blocked by the protein kinase A inhibitor H-89, is mimicked by forskolin, and is therefore thought to be mediated in part through the cAMP/protein kinase A pathway. We have examined deletion mutants of hER for activation by SKF 82958 and find that both its transactivation domains, AF-1 and AF-2, must cooperate to impart the full response to the agonist. Significantly, an agonist of the muscarinic acetylcholine receptor, carbachol, though not active by itself, synergistically activates hER in conjunction with suboptimal doses of SKF 82958. This is the first reported instance of two neurotransmitters synergizing to activate a member of the nuclear receptor superfamily, and might predict a role for multiple neural inputs modulating the effects of these receptors in the central nervous system.

Protein kinase C pathway potentiates androgen-mediated gene expression of the mouse vas deferens specific aldose reductase-like protein (MVDP)

Transcription of the mouse vas deferens protein (MVDP) gene, a member of the aldo-keto reductase superfamily, is stimulated by androgens via the androgen responsive element (ARE) located in the proximal promoter (-111 to -97). We investigated interaction between androgens and the protein kinase C (PKC) signalling pathway. Transcriptional regulation was determined by analysis of chloramphenicol acetyltransferase (CAT). T47D cells were transiently transfected with 5' flanking MVDP DNA promoter sequences (-1804 to +41; -510 to +41 and -121 to +41) fused to the reporter (CAT) gene. Androgen-induced transcriptional activity can be enhanced from 6 (1.8 and 0.5 kb MVDP-CAT constructs) to 18 fold (0.16 kb MVDP-CAT construct), in a time and dose-dependent manner, by the PKC activator 12-o-tetradecanoylphorbol-13 acetate (TPA). A mutation in the proximal ARE abolished both androgen and TPA-dependent gene enhancement. TPA influenced minimally MMTV promoter in T47D cells and MVDP promoter in CV1 cells suggesting that the effects of the PKC activator are probably promoter and cell-specific. In contrast, activation of protein kinase A (PKA) via addition of dibutyryl-cAMP (db-cAMP) reduced androgen induction of the MVDP gene.

Characterization of the promoter of the gene for a mouse vas deferens protein related to the aldo-keto reductase superfamily: effect of steroid hormones and phorbol esters

Mouse vas deferens protein (MVDP) is a member of the aldo-keto reductase family regulated by androgens. The expression of a hybrid gene containing the promoter of the MVDP gene and the chloramphenicol acetyl transferase (CAT) gene coding region was analyzed in two cell lines that do not normally express the MVDP gene: T47D and CV1 cells. A small region of the promoter (-121 to +41) was able to direct significant expression of the reporter gene in both cell lines. Additional elements, between -510 and -121 modulate basal expression in a cell-dependent manner. Interestingly, the 162 bp fragment serves as an androgen-dependent enhancer, and mutation of the consensus ARE sequence located between positions -111 and -97 resulted in a loss of androgen response in both cell lines. Additional elements, upstream of the enhancer, modulate induction positively or negatively in relation to the cell line used. The expression of different MVDP-CAT constructs was more effectively induced by androgens than by glucocorticoids at physiological hormonal concentrations. In addition to the 162 bp enhancer, sequences upstream of -510 were also required for specific androgen regulation. Phorbol 12-myristate 13-acetate (TPA) had no effect on basal activity of the 1.8 kb MVDP-CAT construct but strongly enhanced the induction by androgens.

Synergism between androgens and protein kinase-C on androgen-regulated gene expression

Androgen (R1881) induced transcriptional activity of the human androgen receptor, stably expressed in CHO cells, can be stimulated an extra 2-fold by the addition of the protein kinase C activator, 4 beta-phorbol 12-myristate 13-acetate (PMA). This extra stimulation is not observed when the protein kinase A activator bromoadenosine 3':5'-cyclic monophosphate (8-BrcAMP) is used. The transcriptional activity was measured using a reporter plasmid containing the MMTV-promoter, coupled to the luciferase gene. The effect of PMA on R1881-induced transcription was not due to a higher expression level of the androgen receptor. Also, no extra phosphorylation of the androgen receptor could be measured after incubation with PMA. When GRE-tk-LUC and PSA-LUC reporters were used, the synergistic effect of PMA could not be observed. The findings on the composite MMTV-LTR promoter can be explained by either a direct synergistic interaction between occupied AP-1 like responsive elements and the androgen receptor or via an unknown transcription factor activated by the PKC pathway and interacting with the androgen receptor.

Regulation of uterine collagenase gene expression: interactions between serotonin and progesterone

This report seeks to further define the requirements for the previously established induction of collagenase gene expression by serotonin and inhibition by progesterone in primary cultures of rat uterine smooth muscle cells. Detectable increases in collagenase production were observed after as little as 3 h exposure of cells to 5 microM serotonin, with maximal induction occurring after approximately 8 h of exposure. The apparent half-life of collagenase mRNA upon removal of serotonin was estimated to be approximately 12 h, and was not dependent on the duration of induction. Inhibition by either cycloheximide or progesterone showed similar half lives for collagenase mRNA, however a much shorter half-life (6 h) was obtained in the presence of actinomycin D. These experiments suggest that neither serotonin induction nor progesterone inhibition of collagenase synthesis represents a primary effect on collagenase gene transcription. Rather they appear to be secondary to changes that occur at one or more primary intermediate genes whose induction or decay must occur prior to changes in collagenase transcription. The progesterone receptor antagonist, RU-486, abrogates the ability of progesterone to inhibit serotonin-induced collagenase gene expression, indicating that the effects of progestins in this system likely are receptor-mediated. Finally, the present studies demonstrate that pretreatment of cells for times as long as 5 days with medroxyprogesterone in the absence of serotonin is unable to prevent subsequent serotonin-induced collagenase mRNA increases. These data suggest the possibility of a unique interaction between the molecular pathways of inducer and inhibitor, one in which serotonin may help mediate the progesterone-dependent repression of the levels of collagenase mRNA.

Hormonal control of neural function in the adult brain

Although the mechanisms by which peripheral hormones modulate complex behaviors are far from being well understood, recent advances in deciphering the mechanisms of hormone action in the brain are promising. Current areas of interest include the molecular mechanisms of steroid receptor action, the steroid modulation of synaptic function, and the mediation of steroid-regulated neuronal and glial plasticity by growth factors or proteins associated with brain development.